<?xml version='1.0' encoding='utf-8'?>
<document id="18537523"><sentence text="Emerging lipid-lowering drugs: squalene synthase inhibitors." /><sentence text="Lapaquistat was the only squalene synthase inhibitor in Phase III clinical trials in Europe and the United States, but was recently discontinued from clinical development" /><sentence text=" Unlike statins, the inhibition of de novo cholesterol biosynthesis by lapaquistat does not deplete mevalonate, a precursor of isoprenoids"><entity charOffset="43-54" id="DDI-PubMed.18537523.s3.e0" text="cholesterol" /><entity charOffset="100-110" id="DDI-PubMed.18537523.s3.e1" text="mevalonate" /><entity charOffset="127-138" id="DDI-PubMed.18537523.s3.e2" text="isoprenoids" /><pair ddi="false" e1="DDI-PubMed.18537523.s3.e0" e2="DDI-PubMed.18537523.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18537523.s3.e0" e2="DDI-PubMed.18537523.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18537523.s3.e0" e2="DDI-PubMed.18537523.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18537523.s3.e1" e2="DDI-PubMed.18537523.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18537523.s3.e1" e2="DDI-PubMed.18537523.s3.e2" /></sentence><sentence text=" Isoprenoids are critical in cell growth and metabolism"><entity charOffset="1-12" id="DDI-PubMed.18537523.s4.e0" text="Isoprenoids" /></sentence><sentence text="" /><sentence text="The present review will focus on the chemistry, pharmacology, and lipid-lowering effects of novel squalene synthase inhibitors" /><sentence text="" /><sentence text="A search of Pubmed, IPA, and GoogleScholar for studies (animal and human) and review articles published in English between 1990 and April 2008, using the search terms &quot;squalene synthase inhibitors&quot; or &quot;lapaquistat&quot;" /><sentence text=" All clinical trials identified were then cross-referenced for their citations" /><sentence text=" All literature identified was then complied for this analysis" /><sentence text="" /><sentence text="Lapaquistat mainly targets LDL-C, but may have some effect on HDL-C and TG" /><sentence text=" Preliminary reports on Phase II and Phase III associated lapaquistat 100 mg with elevated hepatic enzymes" /><sentence text=" Hepatotoxicity, possible drug-drug interaction with statins, and the investigation of a statin/coenzyme Q10 combination are among the few challenges that impeded lapaquistat's clinical development" /><sentence text="" /></document>